This is the first book comprising all relevant aspects for the clinical application of biologics. All biologics currently approved for clinical use are described in a standardized way concentrating on practically relevant aspects such as contra-indications or monitoring needs. The "differential therapy" with biologics namely in the fields of dermatology, rheumatology, gastroenterology, and neurology is described in detail and summarized in treatment algorithms. Shorter sections on the biotechnology behind the biologics as well as safety, regulatory, and pharmaco-economic aspects complement the more clinically-oriented central chapters. The book is intended for researchers and clinicians.

First comprehensive book on the new drug generation of biologicals Contains all biologicals presently approved for clinical application Covers all aspects from the biotechnological production processes to the clinical applications Includes safety and regulatory aspects Includes supplementary material: sn.pub/extras

Autorentext

Wolf-Henning Boehncke is a scholar of the German Scholarship Foundation. His research work has been supported by continuous funding from the German Research Foundation (DFG). He was awarded numerous prestigious prizes including the Galenus-von Pergamon Prize. Currently, he is head of the Allergy/Immunology Section at the Center for Dermatology at Frankfurt University. He is a member of numerous national and international boards involved in setting up guidelines for the clinical use of biologicals.

Heinfried H. Radeke is holding the Dr.-Schleussner-Foundation of Immune Pharmacology professorship. His research work has been supported by continuous funding from the German Research Foundation (DFG). His specialization is in pharmacology, clinical pharmacology and immunology. His numerous publications reflect the intensive research he has been doing for the past 15 years in the fields of chronic inflammation, transplantation and immune pharmacology. He is actively involved in the establishment of the new B.Sc./M.Sc. studies in Molecular Medicine at Goethe University Frankfurt. He is also involved in the development of the curricula and the lecture courses of the recently established graduate college "Biologicals" (GK1172) at Goethe University Frankfurt.

Inhalt
Introduction: Definition and Classification of Biologics.- Introduction: Definition and Classification of Biologics.- Development and Pre-clinical Pharmacology of Biologics.- Infliximab: From the Idea to the Product.- Adalimumab.- Etanercept.- Efalizumab: Antibody Characteristics, Mode of Action and Preclinical Development.- Monoclonal Antibody Targeted Radiation Cancer Therapy.- The Production of Biopharmaceuticals.- Disease-Specific Applications and Clinical Trials.- Treating Autoimmune Bullous Skin Disorders with Biologics.- Biologics in Psoriasis.- Biologic Agents in Psoriatic Arthritis.- Biologic Therapies for Rheumatoid Arthritis Targeting TNF-? and IL-1.- Biologics in Crohn's Disease and Ulcerative Colitis: Focus on Tumor Necrosis Factor Antagonists.- Multiple Sclerosis: New Immunobiologics.- Biologics in Cutaneous Lymphoma.- Biologics in Targeted Cancer Therapy.- Safety and Perspectives.- Safety Aspects of Biologics: Lessons Learnt from Monoclonal Antibodies.- New Biological Therapeutics in the Genome Age.- Evidence Based Medicine's Perspective on Biologics.